Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs
Acta Pharmaceutica Sinica B · 2024-11 · 14 (11) · 4665-4682
DOI: 10.1016/j.apsb.2024.09.012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2024-11. Verfasst von Zhenwei Su und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen 518107, China. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Ningbo Municipal Natural Science Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Aluminum adjuvants (Alum), approved by the US Food and Drug Administration, have been extensively used in vaccines containing recombinant antigens, subunits of pathogens, or toxins for almost a century. While Alums typically elicit strong humoral immune responses, their ability to induce cellular and mucosal immunity is limited. As an alternative, layered double hydroxide (LDH), a widely used antacid, has emerged as a novel class of potent nano-aluminum adjuvants (NanoAlum), demonstrating advantageous physicochemical properties, biocompatibility and adjuvanticity in both humoral and cellular immune responses. In this review, we summarize and compare the advantages and disadvantages of Alum and NanoAlum in these properties and their performance as adjuvants. Moreover, we propose the key features for ideal adjuvants and demonstrate that LDH NanoAlum is a promising candidate by summarizing its current progress in immunotherapeutic cancer treatments. Finally, we conclude the review by offering our integrated perspectives about the remaining challenges and future directions for NanoAlum's application in preclinical/clinical settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen 518107, China.
- School of Medicine, Hangzhou City University, Hangzhou 310015, China.
- School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
- Interdisciplinary Nanoscience Center (INANO), Aarhus University, Aarhus 8000, Denmark.
Förderung
- National Natural Science Foundation of China
- Ningbo Municipal Natural Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- EU Framework Programme for Research and Innovation Marie Skłodowska-Curie Actions
Zitieren
APA
Su, Z., Boucetta, H., Shao, J., Huang, J., Wang, R., Shen, A., He, W., Xu, Z. P., & Zhang, L. (2024). Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs. Acta Pharmaceutica Sinica B, 14(11), 4665-4682. https://doi.org/10.1016/j.apsb.2024.09.012
Vancouver
Su Z, Boucetta H, Shao J, Huang J, Wang R, Shen A, et al. Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs. Acta Pharmaceutica Sinica B. 2024;14(11):4665-4682. doi:10.1016/j.apsb.2024.09.012
BibTeX
@article{Su2024,
author = {Su, Zhenwei and Boucetta, Hamza and Shao, Jiahui and Huang, Jinling and Wang, Ran and Shen, Aining and He, Wei and Xu, Zhi Ping and Zhang, Lingxiao},
title = {Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs},
journal = {Acta Pharmaceutica Sinica B},
year = {2024},
volume = {14},
number = {11},
pages = {4665--4682},
doi = {10.1016/j.apsb.2024.09.012}
}
EUVIMED